Latigo Biotherapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Nima Farzan

Chief executive officer

US$7.1m

Total compensation

CEO salary percentage	8.36%
CEO tenure	2.1yrs
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	2yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Nima Farzan's remuneration changed compared to Latigo Biotherapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2026	n/a	n/a	-US$111m
Dec 31 2025	US$7m	US$590k	-US$109m

Compensation vs Market: Nima's total compensation ($USD7.06M) is above average for companies of similar size in the US market ($USD3.54M).

Compensation vs Earnings: Insufficient data to compare Nima's compensation with company performance.

CEO

Nima Farzan (50 yo)

2.1yrs

Tenure

US$7,056,740

Compensation

Mr. Nima Farzan, M.B.A. has been Chief Executive Officer and Director of Latigo Biotherapeutics Inc. since July 2024 and serves as its President. He served as President and Chief Executive Officer at Kinna...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Nima Farzan	CEO, President & Director	2.1yrs	US$7.06m	no data
Neha Krishnamohan	Chief Business Officer & CFO	less than a year	US$620.62k	no data
Neil Singla	Chief Medical Officer	2.3yrs	US$3.45m	0.84% $ 9.9m
Julia Chapman	Senior Vice President of Operations	less than a year	no data	no data
Caroline Dougherty	Vice President of Corporate Development	no data	no data	no data
Bryan Moyer	Senior Vice President of Discovery	no data	no data	no data
Polina German	Senior Vice President of Clinical Pharmacology & Translational	less than a year	no data	no data
Sabrina Nieder	VP & Corporate Controller	less than a year	no data	no data
Vicki Holloway	Secretary	no data	no data	no data

0.5yrs

Average Tenure

50yo

Average Age

Experienced Management: LTGO's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Nima Farzan	CEO, President & Director	2.1yrs	US$7.06m	no data
Kevin Raidy	Independent Director	1.6yrs	no data	no data
James Tananbaum	Independent Director	2.1yrs	no data	no data
Beth Seidenberg	Independent Director	2.1yrs	no data	no data
Timothy Walbert	Independent Chairman	1.8yrs	US$490.21k	0.52% $ 6.1m
Deborah Palestrant	Independent Director	6yrs	no data	no data
Todd Smith	Independent Director	less than a year	no data	no data
Sara Bonstein	Independent Director	less than a year	no data	0.17% $ 2.0m

2.0yrs

Average Tenure

56.5yo

Average Age

Experienced Board: LTGO's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/11 03:38
End of Day Share Price	2026/08/11 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Latigo Biotherapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.